COVID-19 drug repurposing research

ARCA biopharma Provides Update on ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19

Retrieved on: 
Mardi, juillet 13, 2021
Health sciences, Health, Clinical trials, Articles, COVID-19 vaccines, Medical research, COVID-19, Public health, Zoonoses, COVID-19 vaccine, COVID-19 drug repurposing research

The Company also updated its guidance and now anticipates topline data from this international Phase 2b clinical trial in the fourth quarter of 2021.

Key Points: 
  • The Company also updated its guidance and now anticipates topline data from this international Phase 2b clinical trial in the fourth quarter of 2021.
  • ASPEN-COVID-19 is a Phase 2b randomized, multi-center, international clinical trial evaluating two dose regimens of rNAPc2 versus heparin in approximately 160 hospitalized SARS-CoV-2 positive patients that also have an elevated D-dimer level.
  • Other objectives of Phase 2b are to assess safety and determine the optimal dose regimen of rNAPc2 for Phase 3.
  • ARCA is developing rNAPc2 as a potential treatment for diseases caused by RNA viruses, initially focusing on COVID-19.

Inotrem Receives Approval to Expand Nangibotide Clinical Trial in Critically Ill COVID-19 Patients and Receives Additional Public Funding of €45 Million

Retrieved on: 
Lundi, juillet 12, 2021
Health, Infectious diseases, Hospitals, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Nangibotide, Peptides, Medical research, Chemical compounds, Health sciences, Medicine, Abivax, COVID-19 drug repurposing research

This public funding will support Inotrems clinical program including the phase 2/3 study ESSENTIAL which aims to demonstrate the efficacy and safety of nangibotide in treating patients in respiratory distress with severe forms of COVID-19.

Key Points: 
  • This public funding will support Inotrems clinical program including the phase 2/3 study ESSENTIAL which aims to demonstrate the efficacy and safety of nangibotide in treating patients in respiratory distress with severe forms of COVID-19.
  • In ESSENTIAL, a Phase 2/3 clinical program, up to 730 patients will be enrolled initially in France and Belgium and, possibly in other European countries.
  • ESSNTIAL is the continuation of a 60 patients phase 2a evaluating the safety and efficacy of nangibotide in patients suffering from severe COVID-19.
  • Everyone at Inotrem is fully committed to deliver on this ambitious program alongside nangibotides ongoing Phase 2b trial in septic shock patients.

ORYZON Presents Safety and Efficacy Data of Vafidemstat From the Phase II ESCAPE Trial in Severe COVID-19 Patients at ECCMID-2021

Retrieved on: 
Vendredi, juillet 9, 2021
Medical specialties, Health, Medicine, Immunosuppressants, Orphan drugs, Tocilizumab, COVID-19, Acute respiratory distress syndrome, COVID-19 drug repurposing research, RECOVERY Trial

From May 2020 to March 2021, 60 patients were randomized in this Phase II study aiming to determine the safety and efficacy of vafidemstat in COVID-19 severe patients on top of Standard of Care (SoC) treatment.

Key Points: 
  • From May 2020 to March 2021, 60 patients were randomized in this Phase II study aiming to determine the safety and efficacy of vafidemstat in COVID-19 severe patients on top of Standard of Care (SoC) treatment.
  • Of those, 9 AEs were recorded in the vafidemstat plus SoC arm, all mild and considered not treatment-related.
  • A total of 6 patients required rescue medication (Tocilizumab): 4 patients (67%) in the SoC arm and 2 (33%) treated with vafidemstat plus SoC.
  • Vafidemstat is also being explored in a Phase II in severe Covid-19 patients (ESCAPE) assessing the capability of the drug to prevent ARDS, one of the most severe complications of the viral infection.

Verge Genomics Presents Preclinical Data Supporting Broad-Spectrum Potential of Its Novel, Oral Antiviral at the 31st European Congress of Clinical Microbiology & Infectious Diseases

Retrieved on: 
Mercredi, juillet 7, 2021
Health, Infectious diseases, Genetics, Clinical trials, Pharmaceutical, Biotechnology, Coronaviridae, Sarbecovirus, Antiviral drug, Severe acute respiratory syndrome, COVID-19 drug repurposing research, GC376, the Preclinical Study, PIKfyve, Verge Genomics, THE PRECLINICAL STUDY, PIKFYVE, VERGE GENOMICS

The results will be presented at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) online meeting being held July 9-12, 2021.

Key Points: 
  • The results will be presented at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) online meeting being held July 9-12, 2021.
  • There remains an urgent need for oral antiviral treatments for SARS-CoV-2 and its variants, said Alice Zhang, CEO and Co-Founder of Verge Genomics.
  • Verge has demonstrated potent antiviral activity in vitro and improvement of SARS-CoV-2-induced pathology in vivo by the PIKfyve inhibitor, VRG101.
  • Verge is focused on developing therapeutics for serious genetic diseases using human genomics and machine learning.

Prevalence of COVID-19 Among Hospitalized Infants Varies with Levels of Community Transmission

Retrieved on: 
Mercredi, juin 30, 2021
COVID-19, Occupational safety and health, Public health, Zoonoses, Health, Articles, Pediatrics, Preterm birth, COVID-19 drug repurposing research

The study also found rates of COVID-19 positivity in this age group were lower when infection rates in the city were low.

Key Points: 
  • The study also found rates of COVID-19 positivity in this age group were lower when infection rates in the city were low.
  • However, cases of severe illness have been reported and some reports suggest young infants may be at higher risk for severe disease than older children.
  • Among 148 infants, 15 percent tested positive for COVID-19, and two of the 22 infants with COVID-19 required ICU admission, but were discharged safely.
  • The team also found a relatively low incidence (six percent) of infection of the hospitalized infants with other commonly occurring viruses, whether or not they had COVID-19.

RedHill Biopharma Announces Presentation of Positive Oral Opaganib Phase 2 Data in COVID-19

Retrieved on: 
Lundi, juin 21, 2021
Health sciences, Health, Medicine, COVID-19, Occupational safety and health, Public health, Zoonoses, Medical research, Orphan drugs, COVID-19 drug development, COVID-19 drug repurposing research

Phase 2 study were presented in a poster entitled, "Opaganib, an Oral Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: A Randomized, Double-blind, Placebo-controlled Phase 2A Study, in Adult Subjects Hospitalized with SARS-CoV-2 Positive Pneumonia ( NCT: 04414618 )"[2].

Key Points: 
  • Phase 2 study were presented in a poster entitled, "Opaganib, an Oral Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: A Randomized, Double-blind, Placebo-controlled Phase 2A Study, in Adult Subjects Hospitalized with SARS-CoV-2 Positive Pneumonia ( NCT: 04414618 )"[2].
  • "These data, from this proof-of-concept clinical study of opaganib in patients with severe COVID-19, suggest a potential role of SK2 inhibition in combating the effects of this virus.
  • "Presentation of these positive data from our exploratory Phase 2 study support our growing confidence that opaganib could be the first novel, oral therapy to demonstrate efficacy in the treatment of COVID-19 in a large late-stage study.
  • "Opaganib acts on both the cause and effect of COVID-19 via a unique dual antiviral and anti-inflammatory mode of action.

RedHill Biopharma Announces Presentation of Positive Oral Opaganib Phase 2 Data in COVID-19

Retrieved on: 
Lundi, juin 21, 2021
Health sciences, Health, Medicine, COVID-19, Occupational safety and health, Public health, Zoonoses, Medical research, Orphan drugs, COVID-19 drug development, COVID-19 drug repurposing research

Phase 2 study were presented in a poster entitled, "Opaganib, an Oral Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: A Randomized, Double-blind, Placebo-controlled Phase 2A Study, in Adult Subjects Hospitalized with SARS-CoV-2 Positive Pneumonia ( NCT: 04414618 )"[2].

Key Points: 
  • Phase 2 study were presented in a poster entitled, "Opaganib, an Oral Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: A Randomized, Double-blind, Placebo-controlled Phase 2A Study, in Adult Subjects Hospitalized with SARS-CoV-2 Positive Pneumonia ( NCT: 04414618 )"[2].
  • "These data, from this proof-of-concept clinical study of opaganib in patients with severe COVID-19, suggest a potential role of SK2 inhibition in combating the effects of this virus.
  • "Presentation of these positive data from our exploratory Phase 2 study support our growing confidence that opaganib could be the first novel, oral therapy to demonstrate efficacy in the treatment of COVID-19 in a large late-stage study.
  • "Opaganib acts on both the cause and effect of COVID-19 via a unique dual antiviral and anti-inflammatory mode of action.

NRx Pharmaceuticals Announces Positive Results for ZYESAMI™ (Aviptadil-acetate) and Submits Emergency Use Authorization Application to US Food and Drug Administration to Treat Critical COVID-19 in Patients Suffering from Respiratory Failure

Retrieved on: 
Mardi, juin 1, 2021
Health sciences, Health, Organic compounds, Antiviral drugs, COVID-19 drug development, Nitriles, Remdesivir, COVID-19, COVID-19 drug repurposing research, Treatment and management of COVID-19

Patients enrolled in the study had respiratory failure despite prior treatment with all approved medicines for COVID-19 including remdesivir.

Key Points: 
  • Patients enrolled in the study had respiratory failure despite prior treatment with all approved medicines for COVID-19 including remdesivir.
  • ZYESAMI is the first reported medicine to demonstrate increased recovery and survival in patients who have already progressed to respiratory failure.
  • "The positive results from this trial turned into positive implications for some of our sickest COVID-19 patients and support the clinical benefit of ZYESAMI in critically-ill COVID-19 patients with respiratory failure.
  • Separately, the National Institutes of Health is conducting a confirmatory trial that randomizes patients with COVID-19 respiratory failure to ZYESAMIvs.

Results of the COLCORONA study published in The Lancet Respiratory Medicine

Retrieved on: 
Vendredi, mai 28, 2021
Articles, Branches of biology, Chemistry, Orphan drugs, COVID-19, Occupational safety and health, Public health, Zoonoses, Colchicine, Polymerase chain reaction, COVID-19 drug repurposing research

MONTREAL, May 28, 2021 (GLOBE NEWSWIRE) -- The Montreal Heart Institute (MHI) announces that the COLCORONA study results are published in The Lancet Respiratory Medicine.

Key Points: 
  • MONTREAL, May 28, 2021 (GLOBE NEWSWIRE) -- The Montreal Heart Institute (MHI) announces that the COLCORONA study results are published in The Lancet Respiratory Medicine.
  • Our study showed that colchicine could be used to reduce the risk of complications for some patients with COVID-19.
  • The COLCORONA study assessed colchicines potential to reduce the risk of COVID-19-related complications in outpatients over 40 years of age with at least one risk factor for disease progression.
  • Notwithstanding these results, it is recommended that studies such as this one be replicated in non-hospitalized patients with a PCR-confirmed diagnosis of COVID-19.

Results of the COLCORONA study published in The Lancet Respiratory Medicine

Retrieved on: 
Jeudi, mai 27, 2021
Articles, Branches of biology, Chemistry, Orphan drugs, COVID-19, Occupational safety and health, Public health, Zoonoses, Colchicine, Polymerase chain reaction, COVID-19 drug repurposing research

MONTREAL, May 27, 2021 (GLOBE NEWSWIRE) -- The Montreal Heart Institute (MHI) announces that the COLCORONA study results are published today in The Lancet Respiratory Medicine.

Key Points: 
  • MONTREAL, May 27, 2021 (GLOBE NEWSWIRE) -- The Montreal Heart Institute (MHI) announces that the COLCORONA study results are published today in The Lancet Respiratory Medicine.
  • Our study showed that colchicine could be used to reduce the risk of complications for some patients with COVID-19.
  • The COLCORONA study assessed colchicines potential to reduce the risk of COVID-19-related complications in outpatients over 40 years of age with at least one risk factor for disease progression.
  • Notwithstanding these results, it is recommended that studies such as this one be replicated in non-hospitalized patients with a PCR-confirmed diagnosis of COVID-19.